Cholesterol-Lowering Agents

Area of Science:

• Cardiology
• Preventive Medicine
• Lipidology

Background:

• Cardiovascular disease (CVD) is the leading global cause of mortality.
• Low-density lipoprotein cholesterol (LDL-C) is a primary causal factor in atherosclerotic CVD.
• Statin therapy is the current standard for lipid-lowering and CVD risk reduction.

Purpose of the Study:

• To review the established role of statin therapy in CVD prevention.
• To discuss the limitations of current risk prediction models.
• To explore the potential benefits and drawbacks of treating broader populations to shift the LDL-C risk distribution.

Main Methods:

• Literature review of studies on statin efficacy and CVD risk.
• Analysis of risk prediction tools and their accuracy.
• Discussion of the log-linear relationship between LDL-C reduction and CVD risk reduction.

Main Results:

• Statin therapy effectively reduces LDL-C and cardiovascular risk, particularly in secondary prevention and genetic dyslipidemias.
• Most cardiovascular events occur in individuals at moderate to low risk, who are often undertreated.
• Current risk prediction tools may not identify individuals with high lifelong risk but low short-term risk.

Conclusions:

• The effectiveness of statins in reducing LDL-C and CVD risk is well-established.
• A key clinical question is whether to broaden statin treatment to shift the entire population's LDL-C risk distribution.
• This review presents arguments for and against universal or wider LDL-C lowering strategies.